PODD
Company Description
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.71B | 2.07B | 1.70B | 1.31B | 1.10B | 904.40M | 738.20M | 563.82M | 463.77M | 366.99M | 263.89M | 288.72M |
| Net Income | 247.10M | 418.30M | 206.30M | 4.60M | 16.80M | 6.80M | 11.60M | 3.29M | (26.83M) | (28.88M) | (73.52M) | (51.50M) |
| EPS | 3.51 | 5.97 | 2.96 | 0.07 | 0.25 | 0.11 | 0.19 | 0.06 | -0.46 | -0.51 | -1.29 | -0.93 |
| Free Cash Flow | 377.70M | 305.40M | 70.10M | (38.30M) | (190.80M) | (82.50M) | (72.50M) | (126.45M) | (36.02M) | (6.20M) | (23.16M) | (2.57M) |
| FCF / Share | 5.37 | 4.36 | 1.01 | -0.55 | -2.82 | -1.27 | -1.20 | -2.15 | -0.62 | -0.11 | -0.41 | -0.05 |
| Operating CF | 569.30M | 430.30M | 145.70M | 119.00M | (68.10M) | 84.00M | 98.40M | 35.90M | 41.30M | 15.91M | (12.55M) | 8.92M |
| Total Assets | 3.19B | 3.09B | 2.59B | 2.25B | 2.05B | 1.87B | 1.14B | 928.74M | 816.74M | 456.65M | 275.13M | 302.16M |
| Total Debt | 1.05B | 1.42B | 1.45B | 1.43B | 1.29B | 1.08B | 905.90M | 591.98M | 566.17M | 333.04M | 177.49M | 174.64M |
| Cash & Equiv | 716.10M | 953.40M | 650.70M | 623.90M | 791.60M | 907.20M | 203.70M | 113.91M | 272.58M | 137.17M | 122.67M | 151.19M |
| Book Value | 1.52B | 1.21B | 732.70M | 476.40M | 556.30M | 603.60M | 75.90M | 212.10M | 158.52M | 63.15M | 34.05M | 83.83M |
| Return on Equity | 0.16 | 0.35 | 0.28 | 0.01 | 0.03 | 0.01 | 0.15 | 0.02 | -0.17 | -0.46 | -2.16 | -0.61 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 761.70M | 783.80M | 706.30M | 649.10M | 569.00M | 597.50M | 543.90M | 488.50M | 441.70M | 509.80M | 432.70M | 396.50M |
| Net Income | 91.10M | 101.60M | 87.60M | 22.50M | 35.40M | 100.70M | 77.50M | 188.60M | 51.50M | 103.30M | 51.90M | 27.30M |
| EPS | 1.30 | 1.45 | 1.24 | 0.32 | 0.50 | 1.44 | 1.11 | 2.69 | 0.74 | 1.48 | 0.74 | 0.39 |
| Free Cash Flow | 86.00M | 48.20M | 104.70M | 173.30M | 51.50M | 91.70M | 71.80M | 64.30M | 63.60M | 47.20M | 33.60M | 25.90M |
| FCF / Share | 1.23 | 0.69 | 1.48 | 2.46 | 0.73 | 1.31 | 1.02 | 0.92 | 0.91 | 0.68 | 0.48 | 0.37 |
| Operating CF | 113.80M | 183.30M | 125.70M | 196.50M | 63.80M | 147.70M | 98.50M | 86.80M | 87.60M | 45.20M | 56.00M | 44.00M |
| Total Assets | 2.99B | 3.19B | 3.03B | 3.47B | 3.52B | 3.09B | 3.03B | 2.88B | 2.62B | 2.59B | 2.47B | 2.39B |
| Total Debt | 948.10M | 1.05B | 1.03B | 1.42B | 1.70B | 1.42B | 1.40B | 1.40B | 1.40B | 1.45B | 1.42B | 1.40B |
| Cash & Equiv | 480.40M | 716.10M | 757.40M | 992.90M | 1.28B | 953.40M | 902.60M | 715.50M | 696.90M | 650.70M | 580.70M | 556.80M |
| Book Value | 1.30B | 1.52B | 1.38B | 1.46B | 1.33B | 1.21B | 1.12B | 998.40M | 790.70M | 732.70M | 607.50M | 553.90M |
| Return on Equity | 0.07 | 0.07 | 0.06 | 0.02 | 0.03 | 0.08 | 0.07 | 0.19 | 0.07 | 0.14 | 0.09 | 0.05 |